natgillin/translations-raw huggingface dataset:
Patients with elevated liver enzymes alanine aminotransferase (ALT)/aspartate aminotransferase (AST) >2 x ULN or total bilirubin ≥ 1.5 x ULN were excluded in clinical trials.
Bolniki s povečanimi vrednostmi jetrnih encimov alanin-aminotransferaze (ALT)/aspartat- aminotransferaze (AST) > 2-kratna zgornja meja normale ali z vrednostmi skupnega bilirubina ≥ 1,5- kratne zgornje meje normale niso bili vključeni v klinična preskušanja.
Patients with end-stage renal disease receiving dialysis should not exceed 40 mg daily (see section 5.2).
Pri bolnikih z ledvično boleznijo v končnem stadiju, ki prejemajo dializo, odmerek ne sme preseči 40 mg na dan (glejte poglavje 5.2).
Patients with endstage renal failure or severe renal impairment (see sections 4.2 and 5.2)
Bolniki s končno odpovedjo ledvic ali hudo ledvično okvaro (glejte poglavji 4.2 in 5.2)
patients with epilepsy or other central nervous system problems,
bolnikih z epilepsijo ali drugimi motnjami delovanja centralnega živčnega sistema,
Patients with event at 18 months
Bolniki, ki so imeli dogodek v 18 mesecih
Patients with events
0,84 (0,72, 0,98)
Patients with events
0,84 (0,74, 0,95)
Patients with events* (%)
Bolniki z dogodki* (%)
Patients with events, N (%)
Bolniki z dogodki, N (%)
Patients with evidence of compromised bone marrow reserve e.g. following prior cytotoxic chemotherapy and/or radiation treatment (EBRT) or prostate cancer patients with advanced diffuse infiltration of the bone (EOD4; “superscan”) should be treated with caution.
Bolnike z znaki zmanjšane rezerve kostnega mozga, tj. po predhodni citotoksični kemoterapiji in/ali zunanjem obsevanju (EBRT, external beam radiation therapy) ali bolnikih z rakom prostate z napredovalim difuznim kopičenjem v kosteh (EOD4; »superscan«), je treba zdraviti previdno.
Patients with evidence of corneal epithelial breakdown should immediately discontinue use of NEVANAC and should be monitored closely for corneal health.
Bolniki, pri katerih se pojavijo znaki razpadanja roženičnega epitelija, morajo nemudoma prenehati z uporabo zdravila NEVANAC, stanje njihove roženice pa je treba skrbno spremljati.
Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
Bolniki, pri katerih obstajajo dokazi za razpad epitelija roženice, morajo takoj prekiniti uporabo topičnih nesteroidnih protivnetnih zdravil in pri njih je treba skrbno spremljati zdravje roženice.
Patients with existence of or history of severe psychiatric conditions : If treatment with Ribavirin Teva Pharma B.V. in combination with peginterferon alfa-2b or interferon alfa-2b is judged necessary in adult patients with existence or history of severe psychiatric conditions, this should only be initiated after having ensured appropriate individualised diagnostic and therapeutic management of the psychiatric condition.
Bolniki z obstoječimi hudimi psihiatričnimi motnjami ali motnjami v anamnezi: Če ocenite, da je potrebno zdravljenje z zdravilom Ribavirin Teva Pharma B.V. v kombinaciji s peginterferonom alfa- 2b ali interferonom alfa-2b pri odraslih bolnikih z obstoječimi hudimi psihiatričnimi motnjami ali s hudimi psihijatričnimi motnjami v anamnezi, ga smete uvesti šele potem, ko ste zagotovili ustrezno individualno diagnostično in terapevtsko obravnavo psihiatrične motnje.
Patients with existence of or history of severe psychiatric conditions: If treatment with Ribavirin Teva Pharma B.V. in combination with peginterferon alfa-2b or interferon alfa-2b is judged necessary in adult patients with existence or history of severe psychiatric conditions, this should only be initiated after having ensured appropriate individualised diagnostic and therapeutic management of the psychiatric condition.
Bolniki z obstoječimi hudimi psihiatričnimi motnjami ali motnjami v anamnezi: Če ocenite, da je potrebno zdravljenje z zdravilom Ribavirin Teva Pharma B.V. v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b pri odraslih bolnikih z obstoječimi hudimi psihiatričnimi motnjami ali s hudimi psihijatričnimi motnjami v anamnezi, ga smete uvesti šele potem, ko ste zagotovili ustrezno individualno diagnostično in terapevtsko obravnavo psihiatrične motnje.
Patients with existence of, or history of severe psychiatric conditions
Bolniki, ki imajo ali so kdaj imeli hude psihiatrične motnje
Patients with extensive tumour burden due to metastatic disease have been reported to experience progressive hepatic coma and death during azacitidine treatment, especially in such patients with baseline serum albumin
Med zdravljenjem z azacitidinom so poročali o progresivni jetrni komi in smrti bolnikov z razširjeno tumorsko boleznijo zaradi metastatskega obolenja, še zlasti pri bolnikih z izhodiščnim serumskim albuminom < 30 g/l.
Patients with familial hypertriglyceridaemia
Bolniki z družinsko hipertrigliceridemijo
Patients with familial short QT syndrome (see section 4.4).
Bolniki z druţinskim sindromom kratkega intervala QT (glejte poglavje 4.4).
Patients with fistulising Crohn’s disease with acute suppurative fistulas must not initiate Flixabi therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3).
Pri bolnikih s fistulirajočo Crohnovo boleznijo z akutnimi gnojnimi fistulami ne smete uvesti terapije z zdravilom Flixabi, dokler ne izključite možnosti, da obstaja nekje vir okužbe, na primer absces (glejte poglavje 4.3).
Patients with fistulising Crohn’s disease with acute suppurative fistulas must not initiate Inflectra therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3).
Pri bolnikih s fistulirajočo Crohnovo boleznijo z akutnimi gnojnimi fistulami ne smete uvesti terapije z zdravilom Inflectra, dokler ne izključite možnosti, da obstaja nekje vir okužbe, na primer absces (glejte poglavje 4.3).
Patients with fistulising Crohn’s disease with acute suppurative fistulas must not initiate Remicade therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3).
Pri bolnikih s fistulirajočo Crohnovo boleznijo z akutnimi gnojnimi fistulami ne smete uvesti terapije z zdravilom Remicade, dokler ne izključite možnosti, da obstaja nekje vir okužbe, na primer absces (glejte poglavje 4.3).
Patients with fistulising Crohn’s disease with acute suppurative fistulas must not initiate Remsima therapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3).
Pri bolnikih s fistulirajočo Crohnovo boleznijo z akutnimi gnojnimi fistulami ne smete uvesti terapije z zdravilom Remsima, dokler ne izključite možnosti, da obstaja nekje vir okužbe, na primer absces (glejte poglavje 4.3).
Patients with fulminant colitis and patients with multiple episodes (defined as more than one prior episode within the previous 3 months) of CDI were excluded in the studies.
Bolniki s fulminantnim kolitisom in bolniki z več epizodami (opredeljenimi kot več kot ena predhodna epizoda v predhodnih 3 mesecih) CDI so bili iz študij izključeni.
Patients with Gaucher disease should be managed by doctors who are knowledgeable about the disease’s treatment.
Bolnike z Gaucherjevo boleznijo mora zdraviti zdravnik, ki ima izkušnje z zdravljenjem te bolezni.
Patients with genotype 2 CHC
Bolniki s CHC genotipa 2
Patients with GIST will have tried treatment with imatinib and sunitinib.
Bolniki z gastrointestinalnim stromalnim tumorjem bodo poskusili zdravljenje z imatinibom in sunitinibom.
Patients with given number of index/indicator lesion responses (CCR or PR)
Bolniki z dano številko indeksa/indikatorja za odziv lezij (CCR ali PR)
patients with Glanzmann’s thrombasthenia (a rare bleeding disorder) who cannot be treated with a transfusion of platelets (components that help the blood to clot).
pri bolnikih z Glanzmannovo trombastenijo (redko motnjo strjevanja krvi), ki jih ni mogoče zdraviti s transfuzijo trombocitov (sestavina krvi, ki pomaga pri strjevanju krvi).
Patients with Glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of haemolytic anaemia
Bolniki s pomanjkanjem glukoza-6-fosfat-dehidrogenaze (G6PD) zaradi tveganja hemolitične anemije.
Patients with Grade  3 peripheral neuropathy at baseline were excluded from clinical studies.
Bolniki, ki so izhodiščno imeli periferno nevropatijo  3. stopnje, niso bili vključeni v klinične študije.
Patients with growing skeletons
Bolniki s še razvijajočim se skeletom
Patients with HAE have low levels of C4 in the circulation.
Bolniki s HAE imajo v obtoku prenizke ravni C4.
Patients with haemophilia A do not have sufficient blood levels of factor VIII and patients with von Willebrand disease do not have sufficient levels of von Willebrand factor.
Bolniki s hemofilijo A v krvi nimajo zadostne količine faktorja VIII, bolnikom, ki imajo von Willebrandovo bolezen, pa primanjkuje von Willebrandov faktor.
Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems such as bleeding into the joints, muscles and
Bolnikom s hemofilijo A primanjkuje faktorja VIII, tj. beljakovine, ki je potrebna za normalno strjevanje krvi, zato hitreje zakrvavijo in imajo lahko težave, kot so krvavitve v sklepe, mišice in
Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and this causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Bolniki s hemofilijo A imajo pomanjkanje faktorja VIII, tj. beljakovine, ki je potrebna za normalno strjevanje krvi, kar povzroči zaplete pri strjevanju krvi, na primer krvavitve v sklepe, mišice ali notranje organe.
Patients with haemophilia A lack factor VIII, which causes blood clotting problems such as bleeding in the joints, muscles and internal organs.
Bolnikom s hemofilijo A primanjkuje faktorja VIII, kar povzroča zaplete s strjevanjem krvi, kot so krvavitve v sklepe, mišice in notranje organe.
Patients with haemophilia A lack factor VIII, which causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Bolniki s hemofilijo A imajo pomanjkanje faktorja VIII, kar povzroči zaplete pri strjevanju krvi, na primer krvavitve v sklepe, mišice ali notranje organe.
Patients with haemophilia A lack factor VIII, which causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Bolnikom s hemofilijo A primanjkuje faktorja VIII, kar povzroča zaplete s strjevanjem krvi, kot so krvavitve v sklepe, mišice ali notranje organe.
Patients with haemophilia A may develop neutralising antibodies (inhibitors) to factor VIII.
Bolnikom s hemofilijo A se lahko pojavijo nevtralizirajoča protitelesa (zaviralci) proti faktorju VIII.
Patients with haemophilia A may develop neutralising antibodies (inhibitors) to factor VIII.
Pri bolnikih s hemofilijo A lahko nastanejo nevtralizirajoča protitelesa (zaviralci) proti faktorju VIII.
Patients with haemophilia A may develop neutralising antibodies (inhibitors) to factor VIII.
Pri bolnikih s hemofilijo A se lahko razvijejo nevtralizirajoča protitelesa (inhibitorji) proti faktorju VIII.
Patients with haemophilia A may develop neutralising antibodies (inhibitors) to factor VIII.
Pri bolnikih s hemofilijo A se lahko razvijejo nevtralizirajoča protitelesa (zaviralci) proti faktorju VIII.
Patients with haemophilia: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A and B treated with PIs.
Bolniki z hemofilijo: pri bolnikih s hemofilijo tipa A in B, zdravljenih s PI, so se pojavile povečane krvavitve, vključno s spontanimi kožnimi hematomi, in krvavitvami v sklepe.
Patients with haemoptysis (>60 ml) were excluded from the clinical studies so no data exist on the use of TOBI Podhaler in these patients.
Bolnikov s hemoptizo (>60 ml) niso vključevali v klinične študije, zato podatki o uporabi zdravila TOBI Podhaler pri teh bolnikih niso na voljo.
Patients with hemodynamic insufficiency, oedema or hypoproteinaemia
Bolniki s hemodinamsko insuficienco, edemom ali hipoproteinemijo
Patients with Heparin Induced Thrombocytopenia
Bolniki s trombocitopenijo, povzročeno s heparinom
Patients with Heparin Induced Thrombocytopenia
Bolniki s trombocitopenijo, povzročeno s heparinom (heparinska trombocitopenija)
Patients with hepatic and/or renal impairment
Bolniki z jetrno in/ali ledvično okvaro:
Patients with hepatic impairment
Bolnice z jetrno okvaro
Patients with hepatic impairment
Bolniki z jetrno insuficienco
Patients with hepatic impairment
Bolniki z ledvično in jetrno okvaro
Patients with hepatic impairment
Bolniki z motnjami delovanja jeter
Patients with hepatic impairment
Bolniki z motnjami v delovanju jeter
Patients with hepatic impairment
Bolniki z okvara jeter
Patients with hepatic impairment
Okvara jeter
Patients with hepatic impairment (see section 4.3)
Bolniki z okvaro jeter (glejte poglavje 4.3)
Patients with hepatic impairment due to liver metastases.
Bolniki z jetrno okvaro zaradi zasevkov v jetrih.
Patients with hepatic impairment have decreased clearance of amlodipine with resulting increase of approximately 40–60 % in AUC.
Bolniki z okvaro jeter imajo znižan očistek amlodipina; posledica je zvišanje AUC za približno 40-60%.
Patients with hepatic impairment have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC.
Bolniki z okvaro jeter imajo znižan očistek amlodipina; posledica je zvišanje AUC za približno 40-60 %.
Patients with hepatic impairment have not been studied.
Raziskave niso vključevale bolnikov z okvaro jeter.
Patients with hepatic impairment have not been systematically evaluated (see section 5.2).
Bolnikov z okvaro jeter niso sistematično proučili (glejte poglavje 5.2).
Patients with hepatic impairment may be at increased risk of toxicity, particularly Grade 3-4 myelosuppression.
Bolniki z jetrno okvaro so lahko v nevarnosti za zastrupitev, še posebej v primeru mielosupresije 3.–4. stopnje.
Patients with hepatic impairment may receive the recommended starting dose.
Bolniki z okvarjenim delovanjem jeter lahko prejemajo priporočeni začetni odmerek.
Patients with hepatic impairment or renal insufficiency require appropriate monitoring; patients with hepatic impairment should be dosed with caution as there are no data for this patient population (see sections 4.4 and 5.2).
Bolnike z okvaro jeter ali ledvično insuficienco je treba ustrezno spremljati; pri bolnikih z okvaro jeter je treba zdravilo odmerjati previdno, saj podatki za to populacijo bolnikov niso na voljo (glejte poglavji 4.4 in 5.2).
Patients with hepatic impairment should be monitored closely.
Bolnike z okvarjenim delovanjem jeter morate skrbno spremljati.
Patients with hepatic impairment unrelated to their primary disease who are treated with cholic acid are monitored closely.
Bolnike z jetrno okvaro, nepovezano s primarno boleznijo, ki se zdravijo s holno kislino, je treba pozorno spremljati.
Patients with hepatic impairment, including those with pre-treatment ALT or AST > 3x ULN, should not be treated with Eucreas (see sections 4.2, 4.3 and 4.8).
Zdravilo Eucreas se ne sme uporabljati pri bolnikih z okvaro jeter, vključno z bolniki, ki imajo pred zdravljenjem vrednosti ALT ali AST nad 3-kratno zgornjo mejo normalnih vrednosti (glejte poglavja 4.2, 4.3 in 4.8).
Patients with hepatic impairment:
Bolniki z jetrno okvaro
Patients with hepatic impairment:
Bolniki z okvaro jeter:
Patients with hepatic impairment: Erlotinib is eliminated by hepatic metabolism and biliary excretion.
Bolniki z jetrno okvaro: erlotinib se izloča z jetrno presnovo in žolčem.
Patients with hepatic impairment: In a study performed in patients with moderate hepatic impairment (Child-Pugh score 7-9), (n=8), the pharmacokinetics of micafungin did not significantly differ from those in healthy subjects (n=8).
Bolniki z motnjami v delovanju jeter: V študiji, opravljeni pri bolnikih z zmerno motnjo v delovanju jeter (stopnja po Child-Pughu 7–9) (n = 8), se farmakokinetika mikafungina ni pomembno razlikovala od farmakokinetike pri zdravih preizkušancih (n = 8).
Patients with hepatic impairment: It is advised that Corbilta should be administered cautiously to patients with mild to moderate hepatic impairment.
Bolniki z okvaro jeter: Pri bolnikih z blago do zmerno okvaro jeter se priporoča previdnost pri uporabi zdravila Corbilta.
Patients with hepatic impairment: It is advised that Levodopa/Carbidopa/Entacapone Orion should be administered cautiously to patients with mild to moderate hepatic impairment.
Bolniki z okvaro jeter: Pri bolnikih z blago do zmerno okvaro jeter se priporoča previdnost pri uporabi zdravila Levodopa/Carbidopa/Entacapone Orion.
Patients with hepatic impairment: It is advised that Stalevo should be administered cautiously to patients with mild to moderate hepatic impairment.
Bolniki z okvaro jeter: Pri bolnikih z blago do zmerno okvaro jeter se priporoča previdnost pri uporabi zdravila Stalevo.
Patients with hepatic impairment: No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified.
Bolniki z okvarjenim delovanjem jeter: Ugotovili niso nobenih razmerij med AST (SGOT), ALT (SGPT), ali celokupnim bilirubinom in farmakokinetiko pemetrekseda.
Patients with hepatic impairment: Rasagiline use in patients with severe hepatic impairment is contraindicated (see section 4.3).
Bolniki z jetrno okvaro: Uporaba razagilina pri bolnikih s hudo jetrno okvaro je kontraindicirana (glejte poglavje 4.3).
Patients with hepatic impairment: The safety and efficacy have not been studied in patients with hepatic impairment (see section 5.2).
Bolniki z jetrno okvaro: varnosti in učinkovitosti pri bolnikih z okvaro jeter niso proučevali (glejte poglavje 5.2).
Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60 % in AUC.
Pri bolnikih z zmanjšanim jetrnim delovanjem je amlodipinov očistek manjši, zato je njegova AUC za približno 40 do 60 % večja.
Patients with hepatic insufficiency have decreased clearance of amlodipine with resulting increase of approximately 40–60% in AUC.
Bolniki z insuficienco jeter imajo znižan očistek amlodipina; posledica je zvišanje AUC za približno 40-60 %.
Patients with hepatic insufficiency:
Bolniki z oslabljenim delovanjem jeter:
Patients with hepatic or renal impairment have not been investigated.
Bolnikov z jetrno ali ledvično okvaro niso proučevali.
Patients with hereditary angioedema have high levels of a substance called ‘bradykinin’, which is involved in causing inflammation and swelling.
Bolniki z dednim angioedemom imajo visoke koncentracije snovi, imenovane „bradikinin“, ki je vključena v povzročanje vnetja in otekanja.
Patients with hereditary factor X deficiency lack factor X, a protein needed to form the scab (blood clot) that stops wounds from bleeding.
Bolniki z dednim pomanjkanjem faktorja X nimajo dovolj faktorja X, beljakovine, ki je potrebna za nastanek kraste (krvnega strdka), ki zaustavi krvavenje iz rane.
Patients with high baseline HbA1c >10%
Bolniki z visoko izhodiščno vrednostjo HbA1c >10
Patients with high blood pressure
 Bolniki z visokim krvnim tlakom
Patients with high cardiovascular risks – heart failure, type I and poorly controlled type II diabetes and history of myocardial infarction or stroke within one year – were excluded.
Izključeni so bili bolniki z velikim srčno-žilnim tveganjem - s srčnim popuščanjem, z diabetesom tipa 1 ali s slabo urejenim diabetesom tipa 2 ali z miokardnim infarktom, ali možgansko kapjo v zadnjem letu.
Patients with high cardiovascular risks – heart failure, type I and poorly controlled type II diabetes and history of myocardial infarction or stroke within one year – were excluded.
Izključeni so bili bolniki z velikim srčnožilnim tveganjem - s srčnim popuščanjem, z diabetesom tipa 1 ali s slabo urejenim diabetesom tipa 2 ali z miokardnim infarktom, ali možgansko kapjo v zadnjem letu.
Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Toujeo.
Bolnikom, ki zaradi protiteles proti humanemu insulinu potrebujejo velike odmerke insulina, se lahko po prehodu na zdravilo Toujeo odziv na insulin izboljša.
Patients with high MIPI at diagnosis or bulky disease (at least one lesion that is ≥ 7 cm in the longest diameter) at baseline may be at risk of TFR.
Pri bolnikih z visokim MIPI v času diagnoze ali z masivno boleznijo (vsaj ena lezija, ki meri ≥ 7 cm po najdaljšem premeru) v izhodišču lahko obstaja tveganje izbruha tumorja.
Patients with high tumour burden at baseline are at increased risk of early death, 16/81 (20%) early deaths in the lenalidomide arm and 2/28 (7%) early deaths in the control arm.
Pri bolnikih z velikim tumorskim bremenom v izhodišču je tveganje zgodnje smrti večje, v skupini z lenalidomidom je bilo 16/81 (20 %) zgodnjih smrti, v kontrolni skupini pa 2/28 (7 %).
Patients with high tumour burden at baseline are at increased risk of early death, there were 16/81 (20%) early deaths in the lenalidomide arm and 2/28 (7%) early deaths in the control arm.
Pri bolnikih z velikim tumorskim bremenom v izhodišču je tveganje zgodnje smrti večje, v skupini z lenalidomidom je bilo 16/81 (20 %) zgodnjih smrti, v kontrolni skupini pa 2/28 (7 %).
Patients with high tumour burden should therefore be closely monitored for adverse reactions (see Section 4.8) including signs of tumour flare reaction (TFR).
Zato je treba bolnike z velikim tumorskim bremenom skrbno spremljati glede neželenih učinkov (glejte poglavje 4.8), vključno z znaki reakcije izbruha tumorja (TFR).
Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1)
bolniki z zelo aktivno boleznijo, kljub celotnemu in ustreznemu poteku zdravljenja z vsaj enim zdravilom, ki spreminja potek bolezni (DMT-disease modifying therapy) (za izjeme in podatke o vmesnih obdobjih brez zdravljenja glejte poglavji 4.4 in 5.1);
Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1). or
bolniki z zelo aktivno boleznijo kljub celotnemu in ustreznemu poteku zdravljenja z najmanj enim zdravilom, ki spreminja potek bolezni (za izjeme in podatke o vmesnih obdobjih brez zdravljenja glejte poglavji 4.4 in 5.1).
Patients with history of, or current heart failure or left ventricular systolic dysfunction MULTAQ is contraindicated in patients in unstable hemodynamic conditions, with history of, or current heart failure or left ventricular systolic dysfunction (see section 4.3).
Bolniki s srčnim popuščanjem ali sistolično disfunkcijo levega prekata trenutno ali v anamnezi Zdravilo MULTAQ je kontraindicirano pri bolnikih v nestabilnem hemodinamskem stanju, s srčnim popuščanjem ali sistolično disfunkcijo levega prekata trenutno ali v anamnezi (glejte poglavje 4.3).
Patients with HIV
Bolniki s HIV
Patients with HIV
Bolniki, okuženi s HIV
Patients with HIV
Bolniki, okuženi z virusom HIV
Patients with HIV and hepatitis B (HBV) or C virus (HCV) co-infection
Bolniki s sočasno okužbo z virusom HIV in s hepatitisom B (HBV) ali C (HCV)
Patients with HIV and hepatitis B or C virus co-infection
Bolniki s sočasno okužbo s HIV in virusom hepatitisa B ali C
Patients with HIV and hepatitis B or C virus co-infection
Bolniki, sočasno okuženi s HIV in virusom hepatitisa B ali C
Patients with HIV co-infection
Bolniki s sočasno okužbo s HIV
Patients with HIV-1 expressing three or more TAMs that included either the M41L or L210W reverse transcriptase substitution showed reduced response to tenofovir disoproxil fumarate.
Bolniki, pri katerih je HIV-1 izražal tri ali več TAM-e, ki so vsebovali ali M41L ali L210W substitucijo reverzne transkriptaze, so kazali zmanjšani odziv na dizoproksiltenofovirijev fumarat.